Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure

Department of Cardiology, German Heart Center, Munich.

OBJECTIVES. This study was undertaken to determine if a standard dose of aspirin interacts relevantly with the circulatory effects of enalapril in severe heart failure. BACKGROUND. The frequent association of heart failure with coronary artery disease confers potential for combined treatment with an angiotensin-converting enzyme inhibitor and the prostaglandin synthesis inhibitor aspirin, the pharmacodynamic actions of which are, in part, mutually opposed. METHODS. In 18 patients, on 3 consecutive days, hemodynamic measurements were performed at baseline and 4 h after administration of a double placebo, enalapril (10 mg) plus placebo and enalapril plus aspirin (350 mg) according to a double-blind, randomized, crossover protocol. RESULTS. Enalapril given before aspirin led to significant decreases in systemic vascular resistance, left ventricular filling pressure and total pulmonary resistance together with a significant increase in cardiac output. When given with or on the day after aspirin, enalapril did not elicit significant changes in any of these variables. There was a clear tendency to lower values for pulmonary artery pressure on all regimens, and slowing of the heart rate was incurred whether or not aspirin had been given. Chi-square analysis of the individual responses showed that the probability of effecting a decrease in systemic vascular resistance > or = 300 dynes.s.cm-5 was six times greater when enalapril was given without aspirin (p < 0.01). CONCLUSIONS. In severe heart failure, the prostaglandin synthesis inhibition by aspirin counteracts the systemic arterial vasodilation of angiotensin-converting enzyme inhibition with enalapril and substantiates its dependence on the integrity of prostaglandin metabolism. Trends toward reductions of pulmonary artery pressure and slowing of the heart rate were still observed, presumably subsequent to lowered norepinephrine concentrations indicating maintenance of prostaglandin-independent actions of angiotensin-converting enzyme inhibition.

This article has been cited by other articles:

				S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]

				2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]

				B. M. Massie, J. F. Collins, S. E. Ammon, P. W. Armstrong, J. G.F. Cleland, M. Ezekowitz, S. M. Jafri, W. F. Krol, C. M. O'Connor, K. A. Schulman, et al. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Circulation, March 31, 2009; 119(12): 1616 - 1624. [Abstract] [Full Text] [PDF]

				T. Juhlin, B. A.G. Jonsson, and P. Hoglund Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg Eur J Heart Fail, September 1, 2008; 10(9): 892 - 898. [Abstract] [Full Text] [PDF]

				R. P. Riechelmann, I. F. Tannock, L. Wang, E. D. Saad, N. A. Taback, and M. K. Krzyzanowska Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients J Natl Cancer Inst, April 18, 2007; 99(8): 592 - 600. [Abstract] [Full Text] [PDF]

				P. Jhund and J. J.V. McMurray Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?: Choosing Between the Scylla of Observational Studies and the Charybdis of Subgroup Analysis Circulation, June 6, 2006; 113(22): 2566 - 2568. [Full Text] [PDF]

				F. A. Masoudi, P. Wolfe, E. P. Havranek, S. S. Rathore, J. M. Foody, and H. M. Krumholz Aspirin Use in Older Patients With Heart Failure and Coronary Artery Disease: National Prescription Patterns and Relationship With Outcomes J. Am. Coll. Cardiol., September 20, 2005; 46(6): 955 - 962. [Abstract] [Full Text] [PDF]

				B. M. Massie Aspirin Use in Chronic Heart Failure: What Should We Recommend to the Practitioner? J. Am. Coll. Cardiol., September 20, 2005; 46(6): 963 - 966. [Abstract] [Full Text] [PDF]

				T. Juhlin, S. Bjorkman, B. Gunnarsson, A. Fyge, B. Roth, and P. Hoglund Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors Eur J Heart Fail, December 1, 2004; 6(7): 909 - 916. [Abstract] [Full Text] [PDF]

				P. Gaede and O. Pedersen Intensive Integrated Therapy of Type 2 Diabetes: Implications for Long-Term Prognosis Diabetes, December 1, 2004; 53(suppl_3): S39 - S47. [Abstract] [Full Text] [PDF]

				H. P. Brunner-La Rocca Interaction of Angiotensin-Converting Enzyme Inhibition and Aspirin in Congestive Heart Failure: Long Controversy Finally Resolved? Chest, October 1, 2003; 124(4): 1192 - 1194. [Full Text] [PDF]

				V. Aumegeat, N. Lamblin, P. de Groote, E. P. Mc Fadden, A. Millaire, C. Bauters, and J.-M. Lablanche Aspirin Does Not Adversely Affect Survival in Patients With Stable Congestive Heart Failure Treated With Angiotensin-Converting Enzyme Inhibitors Chest, October 1, 2003; 124(4): 1250 - 1258. [Abstract] [Full Text] [PDF]

				C. Meune, J.-J. Mourad, J.-F. Bergmann, and C. Spaulding Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 149 - 154. [Abstract] [PDF]

				T.N. Dzeka, R. Townley, and J.M. O. Arnold Effects of enalaprilat on venoconstriction to norepinephrine: role of prostaglandins Cardiovasc Res, July 1, 2003; 59(1): 250 - 256. [Abstract] [Full Text] [PDF]

				C. Meune, I. Mahe, J.-J. Mourad, A. Cohen-Solal, B. Levy, J.-P. Kevorkian, G. Jondeau, A. Habib, M. Lebret, A.-L. Knellwolf, et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect Eur J Heart Fail, June 1, 2003; 5(3): 271 - 279. [Abstract] [Full Text] [PDF]

				L. E. Spieker, F. T. Ruschitzka, T. F. Luscher, and G. Noll The management of hyperuricemia and gout in patients with heart failure Eur J Heart Fail, August 1, 2002; 4(4): 403 - 410. [Full Text] [PDF]

				H. L. Lazar, Y. Bao, S. Rivers, and S. A. Bernard Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury Ann. Thorac. Surg., May 1, 2002; 73(5): 1522 - 1527. [Abstract] [Full Text] [PDF]

				J. Lindenfeld, A. D. Robertson, B. D. Lowes, M. R. Bristow, and for the MOCHA Investigators Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1950 - 1956. [Abstract] [Full Text] [PDF]

				J. G F Cleland, J. John, J. Dhawan, and A. Clark What is the optimal medical management of ischaemic heart failure? Br. Med. Bull., October 1, 2001; 59(1): 135 - 158. [Abstract] [Full Text] [PDF]

				D. G. Cable Invited commentary Ann. Thorac. Surg., August 1, 2001; 72(2): 553 - 554. [Full Text] [PDF]

				M. Hurlen, T. Hole, I. Seljeflot, and H. Arnesen Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction Eur J Heart Fail, March 1, 2001; 3(2): 203 - 207. [Abstract] [Full Text] [PDF]

				H. M. Krumholz, Y.-T. Chen, Y. Wang, and M. J. Radford Aspirin and Angiotensin-Converting Enzyme Inhibitors Among Elderly Survivors of Hospitalization for an Acute Myocardial Infarction Arch Intern Med, February 26, 2001; 161(4): 538 - 544. [Abstract] [Full Text] [PDF]

				H. M. Krumholz, Y.-T. Chen, and M. J. Radford Aspirin and the Treatment of Heart Failure in the Elderly Arch Intern Med, February 26, 2001; 161(4): 577 - 582. [Abstract] [Full Text] [PDF]

				J. H. O'Keefe, M. Wetzel, R. R. Moe, K. Brosnahan, and C. J. Lavie Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J. Am. Coll. Cardiol., January 1, 2001; 37(1): 1 - 8. [Abstract] [Full Text] [PDF]

				C. D. Frances, H. Noguchi, B. M. Massie, W. S. Browner, and M. McClellan Are We Inhibited?: Renal Insufficiency Should Not Preclude the Use of ACE Inhibitors for Patients With Myocardial Infarction and Depressed Left Ventricular Function Arch Intern Med, September 25, 2000; 160(17): 2645 - 2650. [Abstract] [Full Text] [PDF]

				R. Varin, P. Mulder, F. Tamion, V. Richard, J.-P. Henry, F. Lallemand, G. Lerebours, and C. Thuillez Improvement of Endothelial Function by Chronic Angiotensin-Converting Enzyme Inhibition in Heart Failure : Role of Nitric Oxide, Prostanoids, Oxidant Stress, and Bradykinin Circulation, July 18, 2000; 102(3): 351 - 356. [Abstract] [Full Text] [PDF]

				I. B. Squire, K. P. J. O'Kane, N. Anderson, and J. L. Reid Bradykinin B2 Receptor Antagonism Attenuates Blood Pressure Response to Acute Angiotensin-Converting Enzyme Inhibition in Normal Men Hypertension, July 1, 2000; 36(1): 132 - 136. [Abstract] [Full Text] [PDF]

				R. Latini, G. Tognoni, A. P. Maggioni, C. Baigent, E. Braunwald, Z.-M. Chen, R. Collins, M. Flather, M. Franzosi, J. Kjekshus, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1801 - 1807. [Abstract] [Full Text] [PDF]

				D. Hall The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1808 - 1812. [Full Text] [PDF]

				T. Stys, W. E. Lawson, G. C. Smaldone, and A. Stys Does Aspirin Attenuate the Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Heart Failure? Arch Intern Med, May 22, 2000; 160(10): 1409 - 1413. [Abstract] [Full Text] [PDF]

				J. Page and D. Henry Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem Arch Intern Med, March 27, 2000; 160(6): 777 - 784. [Abstract] [Full Text] [PDF]

				E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]

				M. Guazzi, C. Spaulding, B. Charbonnier, A. Cohen-Solal, Y. Juilliere, E. P. Kromer, K. Benhamda, R. Cador, and S. Weber Hemodynamic Interaction of Aspirin With Enalapril • Response Circulation, December 21, 1999; 100 (25): e141 - e142. [Full Text] [PDF]

				A. P. Davie and J. J. V. McMurray Effect of Angiotensin-(1-7) and Bradykinin in Patients With Heart Failure Treated With an ACE Inhibitor Hypertension, September 1, 1999; 34(3): 457 - 460. [Abstract] [Full Text] [PDF]

				A. P. Davie, H. J. Dargie, and J. J. V. McMurray Role of Bradykinin in the Vasodilator Effects of Losartan and Enalapril in Patients With Heart Failure Circulation, July 20, 1999; 100(3): 268 - 273. [Abstract] [Full Text] [PDF]

				J. Leor, H. Reicher-Reiss, U. Goldbourt, V. Boyko, S. Gottlieb, A. Battler, and S. Behar Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1920 - 1925. [Abstract] [Full Text] [PDF]

				S GALATIUS, H WROBLEWSKI, and J KASTRUP Erratum. Heart, March 1, 1999; 81(3): 330 - 330. [Full Text]

				C. Spaulding, B. Charbonnier, A. Cohen-Solal, Y. Juilliere, E. P. Kromer, K. Benhamda, R. Cador, and S. Weber Acute Hemodynamic Interaction of Aspirin and Ticlopidine With Enalapril : Results of a Double-Blind, Randomized Comparative Trial Circulation, August 25, 1998; 98(8): 757 - 765. [Abstract] [Full Text] [PDF]

				R. P. Shannon, S. Friedrich, M. Mathier, and D. R. Knight Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure Cardiovasc Res, June 1, 1997; 34(3): 464 - 472. [Abstract] [Full Text] [PDF]

				M. Guazzi, G. Marenzi, M. Alimento, M. Contini, and P. Agostoni Improvement of Alveolar–Capillary Membrane Diffusing Capacity With Enalapril in Chronic Heart Failure and Counteracting Effect of Aspirin Circulation, April 1, 1997; 95(7): 1930 - 1936. [Abstract] [Full Text]

				D. W. Baker and R. F. Wright Management of Heart Failure: IV. Anticoagulation for Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction JAMA, November 23, 1994; 272(20): 1614 - 1618. [Abstract] [PDF]

				C. Patrono Aspirin as an Antiplatelet Drug N. Engl. J. Med., May 5, 1994; 330(18): 1287 - 1294. [Full Text]